<p>Nuveen Asset Management LLC 在最近向证券交易委员会的披露中表示，在第四季度将其在 PROCEPT BioRobotics Co. (NASDAQ:PRCT - 免费报告) 的持股减少了 38.1%。该公司在季度内出售了 94,827 股后，持有 153,802 股该公司的股票。截至其最近的 SEC 文件，Nuveen Asset Management LLC 持有的 PROCEPT BioRobotics 的股份约占 0.29%，价值 12,384,000 美元。</p>
<p>获取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
<ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个重大突破吗？</li>
</ul>
<p>其他几家机构投资者也调整了他们在 PRCT 的持股。FMR LLC 在第四季度将其在 PROCEPT BioRobotics 的股份增加了 11.9%。FMR LLC 现在拥有 8,159,208 股该公司的股票，价值 656,979,000 美元，在此期间又购买了 866,328 股。Wellington Management Group LLP 在第四季度将其在 PROCEPT BioRobotics 的股份增加了 38.8%。Wellington Management Group LLP 现在拥有 1,490,952 股该公司的股票，价值 120,051,000 美元，在上个季度又购买了 416,819 股。Vanguard Group Inc. 在第四季度将其在 PROCEPT BioRobotics 的股份增加了 6.1%。Vanguard Group Inc. 现在拥有 5,140,426 股该公司的股票，价值 413,907,000 美元，在上个季度又购买了 297,075 股。Renaissance Technologies LLC 在第四季度购买了 PROCEPT BioRobotics 的新头寸，价值约 22,422,000 美元。最后，Allspring Global Investments Holdings LLC 在第四季度将其在 PROCEPT BioRobotics 的股份增加了 218.1%。Allspring Global Investments Holdings LLC 现在拥有 401,210 股该公司的股票，价值 33,350,000 美元，在上个季度又购买了 275,071 股。机构投资者和对冲基金持有该公司 89.46% 的股份。</p>
<h2>内部活动</h2>
<p>在相关消息中，首席财务官 Kevin Waters 于 3 月 18 日星期二出售了 733 股该公司的股票。股票以平均价格 57.06 美元出售，总交易额为 41,824.98 美元。出售后，首席财务官现在直接持有 107,991 股该公司的股票，价值 6,161,966.46 美元。这代表其持股减少了 0.67%。该交易在向证券交易委员会的文件中披露，可以通过此链接访问。此外，首席执行官 Reza Zadno 于 3 月 18 日星期二出售了 5,475 股该公司的股票。股票以平均价格 57.06 美元出售，总交易额为 312,403.50 美元。出售后，首席执行官现在直接持有 173,070 股该公司的股票，价值约 9,875,374.20 美元。该交易使其持股减少了 3.07%。该交易的披露可以在这里找到。在过去三个月中，内部人士出售了价值 368,322 美元的 6,455 股公司股票。公司内部人士持有该公司 6.60% 的股份。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>为什么 Intuitive Surgical 股票在医疗行业中占据主导地位</li>
</ul>
<p>几位股票分析师最近对该股票发表了看法。Truist Financial 将 PROCEPT BioRobotics 的股票目标价从 90.00 美元下调至 70.00 美元，并在 4 月 11 日的研究报告中给予该股票 &#34;买入&#34; 评级。美国银行将 PROCEPT BioRobotics 的股票目标价从 104.00 美元下调至 84.00 美元，并在 4 月 25 日的研究报告中给予该股票 &#34;买入&#34; 评级。Wall Street Zen 在周六的研究报告中将 PROCEPT BioRobotics 的股票评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。最后，摩根士丹利在 2 月 26 日的研究报告中将 PROCEPT BioRobotics 的股票目标价从 105.00 美元下调至 95.00 美元，并给予该股票 &#34;增持&#34; 评级。两位分析师对该股票给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;适度买入&#34;，共识目标价为 90.00 美元。</p>
<p><strong>查看我们关于 PROCEPT BioRobotics 的最新报告</strong></p>
<h2>PROCEPT BioRobotics 股票表现</h2>
<p>NASDAQ:PRCT 周二开盘价为 57.38 美元。该公司的 50 日移动平均线为 55.27 美元，200 日移动平均线为 70.16 美元。该公司的市值为 31.7 亿美元，市盈率为 -29.43，贝塔系数为 1.10。PROCEPT BioRobotics Co. 的一年低点为 47.04 美元，一年高点为 103.81 美元。该公司的债务与股本比率为 0.21，流动比率为 6.02，速动比率为 5.07。</p>
<p>PROCEPT BioRobotics (NASDAQ:PRCT - 获取免费报告) 最近于 4 月 24 日星期四发布了季度财报。该公司报告季度每股收益（EPS）为 -0.45 美元，超出分析师的共识预期（-0.49 美元）0.04 美元。该业务的季度收入为 6916 万美元，而共识预期为 6539 万美元。PROCEPT BioRobotics 的净利润率为 -50.07%，股本回报率为 -38.57%。该业务的收入同比增长 55.5%。在去年同期，该公司每股收益为 -0.51 美元。分析师预测 PROCEPT BioRobotics Co. 今年将发布 -1.75 美元的每股收益。</p>
<h2>关于 PROCEPT BioRobotics</h2>
<p>(免费报告)</p>
<p>PROCEPT BioRobotics Corporation 是一家外科机器人公司，专注于在美国和国际上开发变革性泌尿学解决方案。该公司开发、制造和销售 AquaBeam 机器人系统，这是一种图像引导的外科机器人系统，旨在用于微创泌尿外科手术，重点治疗良性前列腺增生 (BPH)。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 PROCEPT BioRobotics</li>
<li>如何计算通货膨胀率</li>
<li>Workday 股票价格暴跌：对 AI 投资者来说是自动买入</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>MercadoLibre 正在飙升——你应该等待更好的入场时机吗？</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>对市场有疑虑？三只股票帮助你度过恐惧、不确定性和怀疑</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 PROCEPT BioRobotics 吗？</h2>
<p>在考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在买入的股票，以便在更广泛的市场注意到之前... 而 PROCEPT BioRobotics 并不在名单上。</p>
<p>虽然 PROCEPT BioRobotics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

PRCT

<p>Nuveen Asset Management LLC 在第四季度将其在 PROCEPT BioRobotics Co. (NASDAQ:PRCT) 的持股减少了 38.1%，目前持有 153,802 股，价值 1238 万美元。其他机构投资者，包括 FMR LLC 和 Wellington Management，增加了他们的持股。内部人士的销售包括首席财务官 Kevin Waters 和首席执行官 Reza Zadno 的股票出售。分析师的评级不一，目标价格范围在 70 美元到 95 美元之间。该股票开盘价为 57.38 美元，市值为 31.7 亿美元，市场共识评级为 “适度买入”</p>

<p>Nuveen Asset Management LLC decreased its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 38.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 153,802 shares of the company's stock after selling 94,827 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.29% of PROCEPT BioRobotics worth $12,384,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Nuveen Asset Management LLC 在最近向证券交易委员会的披露中表示，在第四季度将其在 PROCEPT BioRobotics Co. (NASDAQ:PRCT - 免费报告) 的持股减少了 38.1%。该公司在季度内出售了 94,827 股后，持有 153,802 股该公司的股票。截至其最近的 SEC 文件，Nuveen Asset Management LLC 持有的 PROCEPT BioRobotics 的股份约占 0.29%，价值 12,384,000 美元。</p>
</div><p>Get <strong>PROCEPT BioRobotics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
</div><ul>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个重大突破吗？</li>
</ul>
</div><p>Several other institutional investors have also modified their holdings of PRCT. FMR LLC grew its position in shares of PROCEPT BioRobotics by 11.9% in the fourth quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after purchasing an additional 866,328 shares during the period. Wellington Management Group LLP lifted its stake in shares of PROCEPT BioRobotics by 38.8% in the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after buying an additional 416,819 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after buying an additional 297,075 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of PROCEPT BioRobotics in the fourth quarter worth about $22,422,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of PROCEPT BioRobotics by 218.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 401,210 shares of the company's stock worth $33,350,000 after buying an additional 275,071 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者也调整了他们在 PRCT 的持股。FMR LLC 在第四季度将其在 PROCEPT BioRobotics 的股份增加了 11.9%。FMR LLC 现在拥有 8,159,208 股该公司的股票，价值 656,979,000 美元，在此期间又购买了 866,328 股。Wellington Management Group LLP 在第四季度将其在 PROCEPT BioRobotics 的股份增加了 38.8%。Wellington Management Group LLP 现在拥有 1,490,952 股该公司的股票，价值 120,051,000 美元，在上个季度又购买了 416,819 股。Vanguard Group Inc. 在第四季度将其在 PROCEPT BioRobotics 的股份增加了 6.1%。Vanguard Group Inc. 现在拥有 5,140,426 股该公司的股票，价值 413,907,000 美元，在上个季度又购买了 297,075 股。Renaissance Technologies LLC 在第四季度购买了 PROCEPT BioRobotics 的新头寸，价值约 22,422,000 美元。最后，Allspring Global Investments Holdings LLC 在第四季度将其在 PROCEPT BioRobotics 的股份增加了 218.1%。Allspring Global Investments Holdings LLC 现在拥有 401,210 股该公司的股票，价值 33,350,000 美元，在上个季度又购买了 275,071 股。机构投资者和对冲基金持有该公司 89.46% 的股份。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, CFO Kevin Waters sold 733 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the sale, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. This represents a 0.67% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,455 shares of company stock valued at $368,322. Company insiders own 6.60% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Kevin Waters 于 3 月 18 日星期二出售了 733 股该公司的股票。股票以平均价格 57.06 美元出售，总交易额为 41,824.98 美元。出售后，首席财务官现在直接持有 107,991 股该公司的股票，价值 6,161,966.46 美元。这代表其持股减少了 0.67%。该交易在向证券交易委员会的文件中披露，可以通过此链接访问。此外，首席执行官 Reza Zadno 于 3 月 18 日星期二出售了 5,475 股该公司的股票。股票以平均价格 57.06 美元出售，总交易额为 312,403.50 美元。出售后，首席执行官现在直接持有 173,070 股该公司的股票，价值约 9,875,374.20 美元。该交易使其持股减少了 3.07%。该交易的披露可以在这里找到。在过去三个月中，内部人士出售了价值 368,322 美元的 6,455 股公司股票。公司内部人士持有该公司 6.60% 的股份。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 Intuitive Surgical 股票在医疗行业中占据主导地位</li>
</ul>
</div><p>Several equities analysts have recently weighed in on the stock. Truist Financial decreased their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, April 11th. Bank of America decreased their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, April 25th. Wall Street Zen raised shares of PROCEPT BioRobotics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Finally, Morgan Stanley decreased their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an &#34;overweight&#34; rating on the stock in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $90.00.</p>
<div class="lb-trans"><p>几位股票分析师最近对该股票发表了看法。Truist Financial 将 PROCEPT BioRobotics 的股票目标价从 90.00 美元下调至 70.00 美元，并在 4 月 11 日的研究报告中给予该股票 &#34;买入&#34; 评级。美国银行将 PROCEPT BioRobotics 的股票目标价从 104.00 美元下调至 84.00 美元，并在 4 月 25 日的研究报告中给予该股票 &#34;买入&#34; 评级。Wall Street Zen 在周六的研究报告中将 PROCEPT BioRobotics 的股票评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。最后，摩根士丹利在 2 月 26 日的研究报告中将 PROCEPT BioRobotics 的股票目标价从 105.00 美元下调至 95.00 美元，并给予该股票 &#34;增持&#34; 评级。两位分析师对该股票给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;适度买入&#34;，共识目标价为 90.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on PROCEPT BioRobotics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 PROCEPT BioRobotics 的最新报告</strong></p>
</div><h2>PROCEPT BioRobotics Stock Performance</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 股票表现</h2>
</div><p>NASDAQ:PRCT opened at $57.38 on Tuesday. The company's 50-day moving average is $55.27 and its two-hundred day moving average is $70.16. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -29.43 and a beta of 1.10. PROCEPT BioRobotics Co. has a 1-year low of $47.04 and a 1-year high of $103.81. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07.</p>
<div class="lb-trans"><p>NASDAQ:PRCT 周二开盘价为 57.38 美元。该公司的 50 日移动平均线为 55.27 美元，200 日移动平均线为 70.16 美元。该公司的市值为 31.7 亿美元，市盈率为 -29.43，贝塔系数为 1.10。PROCEPT BioRobotics Co. 的一年低点为 47.04 美元，一年高点为 103.81 美元。该公司的债务与股本比率为 0.21，流动比率为 6.02，速动比率为 5.07。</p>
</div><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The business had revenue of $69.16 million for the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business's revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.51) EPS. Analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics (NASDAQ:PRCT - 获取免费报告) 最近于 4 月 24 日星期四发布了季度财报。该公司报告季度每股收益（EPS）为 -0.45 美元，超出分析师的共识预期（-0.49 美元）0.04 美元。该业务的季度收入为 6916 万美元，而共识预期为 6539 万美元。PROCEPT BioRobotics 的净利润率为 -50.07%，股本回报率为 -38.57%。该业务的收入同比增长 55.5%。在去年同期，该公司每股收益为 -0.51 美元。分析师预测 PROCEPT BioRobotics Co. 今年将发布 -1.75 美元的每股收益。</p>
</div><h2>About PROCEPT BioRobotics</h2>
<div class="lb-trans"><h2>关于 PROCEPT BioRobotics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).</p>
<div class="lb-trans"><p>PROCEPT BioRobotics Corporation 是一家外科机器人公司，专注于在美国和国际上开发变革性泌尿学解决方案。该公司开发、制造和销售 AquaBeam 机器人系统，这是一种图像引导的外科机器人系统，旨在用于微创泌尿外科手术，重点治疗良性前列腺增生 (BPH)。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than PROCEPT BioRobotics</li>
<li>How to Calculate Inflation Rate</li>
<li>Workday Stock Price Implosion: An Automatic Buy for AI Investors</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>MercadoLibre Is Soaring—Should You Wait for a Better Entry?</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 PROCEPT BioRobotics</li>
<li>如何计算通货膨胀率</li>
<li>Workday 股票价格暴跌：对 AI 投资者来说是自动买入</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>MercadoLibre 正在飙升——你应该等待更好的入场时机吗？</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>对市场有疑虑？三只股票帮助你度过恐惧、不确定性和怀疑</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PRCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 PROCEPT BioRobotics 吗？</h2>
</div><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在买入的股票，以便在更广泛的市场注意到之前... 而 PROCEPT BioRobotics 并不在名单上。</p>
</div><p>While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PROCEPT BioRobotics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Nuveen Asset Management LLC 出售了 PROCEPT BioRobotics Co.（NASDAQ: PRCT）的股份